In recent years, the cannabis industry has experienced a significant shift in public perception and acceptance. What was once stigmatized as a recreational drug is now being recognized for its potential medicinal benefits. As the industry evolves, new innovations are emerging, pushing the boundaries of what cannabis can offer. One such breakthrough is the development of a synthetic analog of THC, the primary psychoactive compound in cannabis. In this article, we will explore the potential of this synthetic THC and its implications for the future of cannabis.

During a recent podcast episode, we had the opportunity to speak with Erez Aminov and Dr. Adam Kaplin, representatives of Mira Pharmaceuticals, an early-stage life science company. They are currently developing a novel synthetic THC analog called Mira One A. This drug candidate is designed to address anxiety and cognitive impairment, two common issues faced by patients who use THC for medicinal purposes. Mira One A aims to provide a safer alternative for seniors experiencing cognitive decline.